The blood-brain barrier influx-efflux balance drives variability in citalopram brain pharmacokinetics

Aims

Variability in antidepressant (ATD) response represents a major hurdle in clinical psychiatry. While systemic pharmacokinetics, particularly hepatic metabolism (CYP3A4, CYP2C19, CYP2D6), determines plasma ATD concentrations, these systemic parameters do not always correlate with clinical response or efficacy. Such discrepancy may suggest that differences in pharmacodynamic (PD) sensitivity along with intracerebral pharmacokinetics, act as critical additional layers of variability in ATD response. The blood-brain barrier (BBB) actively regulates the drug brain parenchyma access through a balance of efflux transporters, such as P-glycoprotein (ABCB1), and influx mechanisms, including the organic cation proton (H⁺/OC) antiporter. This study aims to characterize how this influx-efflux balance may influence the citalopram brain distribution. Furthermore, we investigated these BBB determinants across the lifespan to better understand the physiological variability of the cerebral drug delivery of citalopram.

Materials and methods

This study utilized an integrative translational framework, combining in silico substrate prediction with validated in vitro and in vivo experimental models. Pharmacophore-modeling was initially employed to map the interaction profile of citalopram with both P-gp and the H⁺/OC antiporter. For the in vitro phase, kinetic studies were performed using the human brain endothelial cell line hCMEC/D3 to quantify influx rates, while MDCK-MDR1 cells were utilized to isolate and evaluate P-gp-mediated efflux. To establish physiological relevance, citalopram brain transport was quantified in vivo through in situ mouse brain perfusion and systemic intraperitoneal (i.p.) administration. These experiments were conducted across a broad developmental range, including neonates (two weeks), adults, and aged mice (nine months). We specifically investigated transport kinetics and potential enantioselectivity (using R- and S-citalopram) to clarify the impact of BBB transporter activity on stereoisomeric distribution.

Results

Pharmacophore-modeling successfully identified citalopram as a substrate for the H⁺/OC antiporter. In hCMEC/D3 cells, citalopram exhibited first-order influx at therapeutic concentrations, suggesting that H⁺/OC antiporter activity facilitates its initial entry into the brain parenchyma. No enantioselectivity was found, as both S- and R-enantiomers of citalopram interacted similarly with the transporters. Notably, citalopram showed significant P-gp-mediated efflux in both MDCK-MDR1 cells and the mouse BBB, distinguishing its profile from several other ATDs. The in vivo data revealed a dynamic interplay between P-gp-mediated restricted entry and H⁺/OC-mediated influx at the BBB. We observed a significant age-related decline in citalopram brain permeability compared to younger animals, suggesting that BBB transport capacity/balance undergoes physiological modifications in aged mice.

Conclusions

Although citalopram was previously identified as a P-gp substrate our findings identify that much importantly the balance between H⁺/OC antiporter-mediated influx and P-gp-mediated efflux is the key determinant of citalopram brain distribution and a source of pharmacokinetic variability. The age-related decline in citalopram mouse brain permeability further indicates that the regulation of their activity impacts citalopram brain transport which may be reduced in the elderly population. Altogether, this neuro-pharmacokinetic framework provides a more integrated understanding of ATD variability and identifies the BBB as a critical determinant that opens new hypotheses for optimizing better ATD therapy.

References

No references